Results 1 to 10 of about 2,492,664 (191)
Ofatumumab: a novel monoclonal anti-CD20 antibody
Pharmacogenomics and Personalized Medicine, 2010 Thomas S LinGlaxoSmithKline Oncology R&D, Collegeville, PA, USAAbstract: Ofatumumab, a novel humanized monoclonal anti-CD20 antibody, was recently approved by the FDA for the treatment of fludarabine and alemtuzumab refractory chronic lymphocytic
Thomas S Lin
doaj +7 more sources
Anti-CD20 Monoclonal Antibodies: Reviewing a Revolution [PDF]
Human Vaccines and Immunotherapeutics, 2018 Since the inception of rituximab in the 1990s, anti-CD20 monoclonal antibodies have revolutionised the treatment of B cell hematological malignancies and have become a cornerstone of modern gold-standard practice. Additionally, the potent efficacy of these agents in depleting the B cell compartment has been used in the management of a broad array of ...
Stephen Opat
exaly +6 more sources
Journal of Genetic Engineering and Biotechnology, 2022 Background Recombinant therapeutic anti-CD20 monoclonal antibody (mAb) is used for the treatment of non-Hodgkin’s lymphoma, a common B cell lymphoma constituting 80% of all lymphomas. Anti-CD20 mAb contains an Fc-linked biantennary glycan. Although, anti-
Bala Reddy Bheemareddy +3 more
doaj +2 more sources
Application of anti-CD20 monoclonal antibodies in the treatment of lymphoproliferative diseases [PDF]
Archive of Oncology, 2009 Out of numerous studied monoclonal antibodies, only a few reached the stage of clinical application. The CD20 molecule, non-glycolysed phospholipoprotein (usually termed B1), belonging to the tetraspan (TM4SF) family, 35-37 kD, is characteristic for all ...
Pejčić Ivica, Vrbić Svetislav
doaj +2 more sources
Anti-CD20 monoclonal antibodies in membranous nephropathy
NefrologíaNovel anti-CD20 monoclonal antibodies have been developed to optimize B-cell depletion. A key mechanism of action of these therapeutic monoclonal antibodies is the activation of immune cells via Fc receptors (FcγR).
Juan Daniel Díaz-García +6 more
doaj +4 more sources
The Future of Anti-CD20 Monoclonal Antibodies: Are We Making Progress? [PDF]
Blood, 2011 AbstractThe anti-CD20 monoclonal antibody (mAb) rituximab has revolutionized the treatment of B-cell malignancies. This unprecedented success has not only substantially changed the mindset of the clinical community about the ability of mAb to improve outcomes but has catalyzed the interest in the pharmaceutical industry to develop the next generation ...
Tim M. Illidge, Waleed Alduaij
exaly +3 more sources
Anti-CD20 monoclonal antibodies in Systemic Lupus Erythematosus [PDF]
Biologicals, 2021 Systemic Lupus Erythematosus (SLE) is an autoimmune inflammatory condition with a wide spectrum of disease manifestations and severities, resulting in significant morbidity and mortality. The aetiopathogenesis of SLE is complex. Young women and certain ethnicities are commonly affected, suggesting a significant hormonal and genetic influence.
Shah, K, Cragg, M, Leandro, M, Reddy, V
openaire +3 more sources
ACR Open Rheumatology, 2022 Objective Patients with immune‐mediated diseases treated with anti‐CD20 monoclonal antibodies may have worse coronavirus disease 2019 (COVID‐19) outcomes due to impaired humoral immunity, but differences compared with the general population are unknown ...
Naomi J. Patel +12 more
doaj +1 more source
Anti-CD20 Agents for Multiple Sclerosis: Spotlight on Ocrelizumab and Ofatumumab
Brain Sciences, 2020 Until recently, in the pathogenesis of Multiple Sclerosis (MS), the contribution of B cells has been largely underestimated, and the disease was considered a T-cell-mediated disorder.
Despoina Florou +4 more
doaj +1 more source
Anti‐CD20 monoclonal antibody therapy in postpartum women with neurological conditions
Annals of Clinical and Translational Neurology, 2023 Objective Postpartum, patients with multiple sclerosis (MS) and neuromyelitis optica spectrum disorder (NMOSD) have increased risk for disease activity. Anti‐CD20 IgG1 monoclonal antibodies (mAb) are increasingly used as disease‐modifying therapies (DMTs)
Annika Anderson +22 more
doaj +1 more source